Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACTR087 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ACTR087, in combination with rituximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ACTR087 | BIOLOGICAL | - |
| rituximab | BIOLOGICAL | - |
Inclusion Criteria: * Signed written informed consent obtained prior to study procedures * Histologically-confirmed relapsed or refractory CD20+ B-cell lymphoma of one of the following types, with documented disease progression or recurrence following the immediate prior therapy: * DLBCL, regard...
Top 20 of 66 competitors
ACTR087 is an investigational monoclonal antibody being studied for the treatment of lymphoma, specifically in patients with relapsed or refractory B-cell lymphoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ACTR087 is being developed by Cogent Biosciences, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol COGT. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
ACTR087 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains under investigation for its potential use in lymphoma.
ACTR087 has been studied in one clinical trial with the identifier NCT02776813, titled "Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma." This Phase 1 trial was completed and enrolled 34 participants in the United States.
No, ACTR087 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial evaluated its use in relapsed or refractory B-cell lymphoma, but further studies are needed before it can be considered for regulatory approval.